Meeting Banner
Abstract #1638

Evaluation of MRI as an Outcome Measure for Therapeutic Trials in Muscular Dystrophy Mice

Khan Hekmatyar1, Steven J. Foltz2, Marisa J. Fortunato2, Aaron M. Beedle2

1BioImaging Research Center/Complex Carbohydrate Research Center, University of Georgia, Athens, GA, United States; 2Department of Pharmaceutical and Biomedical Sciences, University of Georgia College of Pharmacy, Athens, GA, United States

Abnormal glycosylation of α-dystroglycan impairs the structural link between the extracellular matrix and the cytoskeleton causing dystroglycanopathy-type muscular dystrophy. There are no validated therapies for dystroglycanopathies and variability in phenotypes complicates the assessment of therapeutic effect. Our aim is to assess the correlation between relaxometric measurements (T2) in magnetic resonance (MR) imaging and histological measurements to determine the reliability and suitability of MR imaging for future therapeutic trials in animal models.